Agios Pharmaceuticals (AGIO) Free Cash Flow (2012 - 2026)

Agios Pharmaceuticals has reported Free Cash Flow for 15 years, with the latest figure at -$119.6 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow fell 7.05% year-over-year to -$119.6 million; the trailing twelve-month figure through Mar 2026 stood at -$385.2 million (up 4.51% YoY), and the FY2025 full-year result was -$377.3 million, up 3.64% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$119.6 million, down from -$97.3 million in the prior quarter.
• The five-year high for Free Cash Flow was -$62.4 million in Q3 2023, with the low at -$134.1 million in Q4 2024.
• Historically, Free Cash Flow has averaged -$88.2 million across 5 years, with a median of -$84.6 million in 2024.
• The largest YoY upside for Free Cash Flow was 53.37% in 2022 against a maximum downside of 1805.51% in 2022.
• Agios Pharmaceuticals' Free Cash Flow stood at -$66.3 million in 2022, then declined by 8.3% to -$71.8 million in 2023, then tumbled by 86.87% to -$134.1 million in 2024, then increased by 27.44% to -$97.3 million in 2025, then dropped by 22.86% to -$119.6 million in 2026.
• The last three Free Cash Flow figures came in at -$119.6 million (Q1 2026), -$97.3 million (Q4 2025), and -$89.7 million (Q3 2025), per Business Quant data.